GL1X · GenesisL1 explorer

MolNFT v1 · #168304 · protein

Human cftr first nucleotide binding domain with DF508/V510D

6WBS · Cystic fibrosis transmembrane conductance regulator: “Human cftr first nucleotide binding domain with DF508/V510D”. X-ray diffraction, 2 ligands (ATP, MG), 4 pockets (best druggability 0.70). MolNFT v1 #168304 on GenesisL1: 3D…

PDB
6WBS
Type
protein
Length
440 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cystic fibrosis transmembrane conductance regulator
EC
5.6.1.6
UniProt
P13569
Ligands
ATP, MG
Pockets
4 · best druggability 0.70

Structure

x-ray diffraction · 2 distinct chains · 35% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACystic fibrosis transmembrane conductance regulator (EC 5.6.1.6)protein21533% helix, 28% strandP13569
BCystic fibrosis transmembrane conductance regulator (EC 5.6.1.6)protein22537% helix, 27% strandP13569

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17780.700.7774empty
22360.470.7332empty
31050.360.7522empty
4710.300.7417empty

Interfaces

1 interface between chains.

  • A–B · 498 Ų buried · 15 hydrogen bonds · protein-protein

Compared structures

  • 6WBS · Human CFTR first nucleotide binding domain with dF508/V510D · the same entry in another collection · chain A against A, TM-score 1.00
  • P13569 · AlphaFold monomer V2.0 prediction for cystic fibrosis transmembrane conductance regulator… · a predicted model of the same protein · chain A against A, TM-score 0.96

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.